Literature DB >> 28848862

Daily Peak Expiratory Flow Rate and Disease Instability in Chronic Obstructive Pulmonary Disease.

Jennifer Y So1, Alejandra C Lastra1, Huaqing Zhao1, Nathaniel Marchetti1, Gerard J Criner1.   

Abstract

Rationale: Chronic obstructive pulmonary disease, (COPD) is a major cause of morbidity and mortality in the United States. Peak expiratory flow rate (PEFR) monitoring could provide a daily objective measurement of lung function in COPD patients at home. We hypothesized that individuals with greater variability in daily PEFR would signal an unstable patient population with worse outcomes.
Methods: This was a retrospective analysis of prospectively collected data using an electronic diary to record daily PEFR and symptoms in severe and very severe COPD patients. Rates of PEFR change were used to characterize patients into stable and unstable groups determined by the distribution of slopes. Exacerbation-free days, time to first hospitalization, hospitalization rate, length of hospitalization, and all-cause mortality were assessed.
Results: A total of 104 severe and very severe COPD patients met entry criteria, and were observed for 37,702 patient-days. There were no significant differences in baseline symptoms, demographics, forced expiratory volume in 1 second (FEV1) or comorbidities between stable versus unstable groups. The unstable group had 34.7 less exacerbation-free days and significantly shorter 6 minute walk distances (6MWD) (227.1 versus 270.7 meters, p=0.031), shorter time to first hospitalization (163 versus 286 days, p=0.017), more frequent hospitalizations (2.6 versus 1.7 per year, p=0.032) and higher all-cause mortality (10.8 versus 5.1%, p= 0.04).
Conclusion: Patients with severe to very severe COPD with greater changes in PEFR have shorter 6MWD, reduced time to first hospitalization, more frequent hospitalizations, and higher all-cause mortality despite similar demographic, spirometric and comorbid parameters at baseline. Daily peak flow monitoring can be a useful tool in identifying COPD patients predisposed to worse outcomes.

Entities:  

Keywords:  COPD; chronic obstructive pulmonary disease; exacerbation; peak flow

Year:  2015        PMID: 28848862      PMCID: PMC5559121          DOI: 10.15326/jcopdf.3.1.2015.0142

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  16 in total

1.  Patient compliance with peak flow monitoring in chronic obstructive pulmonary disease.

Authors:  G H Murata; C O Kapsner; D J Lium; H K Busby
Journal:  Am J Med Sci       Date:  1998-05       Impact factor: 2.378

Review 2.  Utility of peak expiratory flow monitoring.

Authors:  P Jain; M S Kavuru; C L Emerman; M Ahmad
Journal:  Chest       Date:  1998-09       Impact factor: 9.410

3.  CD4 T-lymphocyte activation is associated with peak expiratory flow variability in childhood asthma.

Authors:  S Doi; N Murayama; T Inoue; I Takamatsu; M Kameda; Y Omoto; K Toyoshima
Journal:  J Allergy Clin Immunol       Date:  1996-04       Impact factor: 10.793

4.  Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

5.  Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

Authors:  J J Soler-Cataluña; M A Martínez-García; P Román Sánchez; E Salcedo; M Navarro; R Ochando
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

6.  Interpretation of the variability of peak flow rates in chronic bronchitis.

Authors:  E H Ramsdale; M M Morris; F E Hargreave
Journal:  Thorax       Date:  1986-10       Impact factor: 9.139

7.  Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

Authors:  G C Donaldson; T A R Seemungal; A Bhowmik; J A Wedzicha
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

8.  Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease.

Authors:  Tom M A Wilkinson; Gavin C Donaldson; John R Hurst; Terence A R Seemungal; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2004-02-27       Impact factor: 21.405

9.  Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort.

Authors:  Lisa Langsetmo; Robert W Platt; Pierre Ernst; Jean Bourbeau
Journal:  Am J Respir Crit Care Med       Date:  2007-11-29       Impact factor: 21.405

10.  Bronchodilator responsiveness in patients with COPD.

Authors:  D P Tashkin; B Celli; M Decramer; D Liu; D Burkhart; C Cassino; S Kesten
Journal:  Eur Respir J       Date:  2008-02-06       Impact factor: 16.671

View more
  8 in total

1.  Pulmonary function testing during the COVID-19 pandemicin.

Authors:  Devasahayam Jesudas Christopher; B V Murali Mohan; Rupak Singla; Parvaiz A Koul
Journal:  Lung India       Date:  2021-03

Review 2.  Accuracy of portable spirometers in the diagnosis of chronic obstructive pulmonary disease A meta-analysis.

Authors:  Na Yu; Wei Wang; Jiawei Zhou; Xiaomeng Li; Xingjian Wang
Journal:  NPJ Prim Care Respir Med       Date:  2022-04-19       Impact factor: 3.289

3.  Body Composition of Filipino Chronic Obstructive Pulmonary Disease (COPD) Patients in Relation to Their Lung Function, Exercise Capacity and Quality of Life.

Authors:  Jamie R Chua; Albert B Albay; Michael L Tee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-12-02

4.  Remote Patient Monitoring for the Detection of COPD Exacerbations.

Authors:  Christopher B Cooper; Worawan Sirichana; Michael T Arnold; Eric V Neufeld; Michael Taylor; Xiaoyan Wang; Brett A Dolezal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-08-24

5.  Peak expiratory flow is a reliably household pulmonary function parameter correlates with disease severity and survival of patients with amyotrophic lateral sclerosis.

Authors:  Qi-Jie Zhang; Jian-Chai Huang; Jia Chen; Wei Hu; Liu-Qing Xu; Qi-Fu Guo
Journal:  BMC Neurol       Date:  2022-03-19       Impact factor: 2.474

6.  Preventing clinically important deterioration with single-inhaler triple therapy in COPD.

Authors:  Ian Naya; Chris Compton; Afisi S Ismaila; Ruby Birk; Noushin Brealey; Maggie Tabberer; Chang-Qing Zhu; David A Lipson; Gerard Criner
Journal:  ERJ Open Res       Date:  2018-10-03

7.  Clinical, laboratory, and functional characteristics of asthma-COPD overlap in patients with a primary diagnosis of COPD.

Authors:  Ana Paula Adriano Queiroz; Fernanda Rodrigues Fonseca; Alexânia de Rê; Rosemeri Maurici
Journal:  J Bras Pneumol       Date:  2020-11-06       Impact factor: 2.624

8.  Going beyond the mean in examining relationships of adolescent non-cognitive skills with health-related quality of life and biomarkers in later-life.

Authors:  Rose Atkins; Alex James Turner; Tarani Chandola; Matt Sutton
Journal:  Econ Hum Biol       Date:  2020-09-02       Impact factor: 2.774

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.